Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass

Re-Adjustment of Sweep Gas Flow to the During the Rewarming Period of the Cardiopulmonary Bypass to Prevent Alkalosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06013189

Enrollment

Registered

2023-08-28

Start date

2023-08-07

Completion date

2034-11-30

Last updated

2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Determination of Optimal Sweep Gas Flow for Different Phases of Cardiopulmonary Bypass, Optimal Sweep Gas Flow

Keywords

sweep gas flow, rewarming, cardiopulmonary bypass, alkalosis

Brief summary

The investigators designed this prospective observational study with the theory that alkalosis caused by decreased CO2 solubility due to temperature increase during the rewarming period of the Cardiopulmonary Bypass could be prevented by reducing the sweep gas flow during the rewarming period.

Interventions

OTHERGas Flow Adjustment

Decreased gas flow causes PaCO2 to elevate and prevents alkalosis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age * Elective CPB surgery

Exclusion criteria

* Patients undergoing minimally invasive surgery * Patients undergoing robotic cardiac surgery, * Patients undergoing deep hypothermia, * Patients undergoing total circulatory arrest, * Patients whose FiO2 requirement is high that cannot be applied to target gas flow

Design outcomes

Primary

Measure	Time frame	Description
Arterial pH lever lower than 7.30	during the cardiopulmonary bypass and postoperative 24th hour	maintaining physiological pH

Secondary

Measure	Time frame	Description
rSO2 20% below initial value	during the cardiopulmonary bypass	observing the rSO2 of brain during rewarming period

Countries

Turkey (Türkiye)

Contacts

Primary ContactMelis Tosun, MD

melistosun@gmail.com00905356694002

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026